Good morning and happy Friday. Here is what I am reading as we head into the weekend:
- Amazon buying PillPack is a big deal as it gives them an easy pass to being licensed in the various states (Forbes). I imagine it will be a good weekend for the 32 year old owner who sold to Amazon (Forbes).
- Akebia and Keryx are merging, but the market did not react well (Marketwatch).
- It take patience to endure a three year clinical trial hold, but that’s what Aptose did and now they are free to proceed (Endpoints).
- MIT Media Lab has developed a personalized learning machine that will estimate the engagement and interest of autistic children during therapy sessions (Verdict Medical Devices).
